NASDAQ:ALKSAlkermes Stock Price, Forecast & News

Alkermes' stock was trading at $16.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALKS stock has increased by 2.6% and is now trading at $16.67. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 11 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alkermes.

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Alkermes.

Alkermes Plc (NASDAQ:ALKS) issued its quarterly earnings results on Wednesday, April, 29th. The company reported $0.01 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.07. The company earned $246.20 million during the quarter, compared to the consensus estimate of $230.53 million. Alkermes had a negative net margin of 11.63% and a positive return on equity of 4.99%. The firm's revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.17) EPS. View Alkermes' earnings history.

12 brokerages have issued 1 year price objectives for Alkermes' stock. Their forecasts range from $16.00 to $28.00. On average, they expect Alkermes' stock price to reach $21.17 in the next twelve months. This suggests a possible upside of 27.0% from the stock's current price. View analysts' price targets for Alkermes.

News articles about ALKS stock have trended positive recently, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alkermes earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the next several days. View the latest news aboutAlkermes.

Alkermes saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 9,290,000 shares, an increase of 16.6% from the April 15th total of 7,970,000 shares. Based on an average trading volume of 2,020,000 shares, the days-to-cover ratio is presently 4.6 days. Approximately 5.9% of the shares of the company are sold short. View Alkermes' Current Options Chain.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Starbucks (SBUX), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (13.82%), Primecap Management Co. CA (5.67%), BlackRock Inc. (5.55%), Sarissa Capital Management LP (4.53%), Camber Capital Management LP (3.81%) and State Street Corp (2.98%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Two Sigma Investments LP, BlackRock Inc., Deutsche Bank AG, Engineers Gate Manager LP, Rafferty Asset Management LLC, Spark Investment Management LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops. View insider buying and selling activity for Alkermes.

ALKS stock was bought by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Maverick Capital Ltd., Camber Capital Management LP, BNP Paribas Arbitrage SA, Invesco Ltd., Atom Investors LP, UBS Group AG, and Krensavage Asset Management LLC. View insider buying and selling activity for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $16.67.

Alkermes has a market capitalization of $2.65 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]